Pfizer expects revenues from its BioNTech-partnered COVID-19 vaccine to reach an eye-watering $26 billion this year, catapulting it to the top of the world's biggest-selling medicines.
Ken Frazier's final appearance on Merck & Co's financial results call as chief executive was a muted affair, as the company reported lower-than-expected revenues dragged down as the pan